We are examining the long-term safety and tolerability of EDG-5506 in adults and adolescents with Becker Muscular Dystrophy. This study aims to understand how well the treatment is tolerated over time.
Health conditions and diseases that the clinical trial is designed to study and treat.
Becker's Muscular Dystrophy (BMD) is a rare genetic disorder that leads to progressive muscle weakness and wasting, primarily affecting the skeletal muscles. It is caused by mutations in the dystrophin gene, resulting in symptoms that typically appear in adolescence or early adulthood.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
